ClinicalTrials.gg
Not yet recruitingNCT07846735YOURSUpdated Sep 29, 2026

Youth Overdose & Use Reduction in Rural Systems

An interventional study of Navigator - Flexible Care Management in Substance Abuse, Opioid Abuse (Disorder) and Overdose Prevention, sponsored by Seattle Children's Hospital. Not yet recruiting. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionOpioid-Related DisordersRegistry: Substance-Related DisordersReclassifiedWhy we changed it
Registry
Substance-Related Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Opioid-Related Disorders
Why
  1. The study's listed conditions name Opioid-Related Disorders, a narrower term within Substance-Related Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Health services research

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Study summary

The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.

The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.

The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.

Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.

Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.

Read the detailed description

Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.

Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.

Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.

02

Conditions studied

  • Substance Abuse
  • Opioid Abuse (Disorder)
  • Overdose Prevention
  • Substance Use Disorder (SUD)
  • Adolescent Substance Use
  • Rural Health

Browse trials for

03

In context

Opioid-Related Disorders Reclassified

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

This study's planned enrollment of 550 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Seattle Children's Hospital is the lead sponsor of 217 studies on the registry; 46 are open to participants now.

Compared within Opioid-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Youth age 14-18
  • Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
  • Received a REDCap link or QR code and study participation code from authorized county staff

Exclusion criteria

Exclusion Criteria:

  • Youth age 13 and under
  • Youth who do not receive a study participation code from an authorized county contact
  • Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Intervention: YOURS Navigator Program

    The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties.

    Behavioral: Navigator - Flexible Care Management

  • No intervention
    Usual Care

    No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways.

Interventions

  • BehavioralNavigator - Flexible Care Management

    Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.

    Also known as: Care Management, ACRA/ACC, Assertive Continuing Care (ACC)

06

What researchers measure

Primary outcomes

  1. Overdose Prevention Knowledge

    Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome.

    Time frame: 3- and 6-months

  2. Presence of use past 30 days (Yes/No)

    Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days

    Time frame: 3- and 6-months

  3. Number of days using alcohol and cannabis

    In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol.

    Time frame: 3- and 6-months

  4. Number of youth receiving case management, mental health, or substance use prevention services

    Primary implementation outcome - county level

    Time frame: Through study completion, up to 30 months

  5. Number of naloxone kits distributed

    Primary implementation outcome - county level

    Time frame: Through study completion, up to 30 months

Secondary outcomes

  1. Number of days of using other individual non-alcohol/non-cannabis substances

    Measure taken from the HEAL Prevention Cooperative Common Core Measures

    Time frame: 3- and 6- months

  2. Substance use refusal self-efficacy

    How confident youth are resisting substances.

    Time frame: 3- and 6-months

  3. Percent of youth reporting receipt of naloxone

    Percent of youth receiving naloxone, a medication to reverse an opioid overdose.

    Time frame: 3 months

  4. Number of youth receiving overdose prevention education

    Secondary implementation outcome - county level

    Time frame: Through study completion, up to 30 months

  5. Number of court staff receiving overdose prevention education

    Secondary implementation outcome - county level

    Time frame: Through study completion, up to 30 months

Other outcomes

  1. Presence of non-fatal overdose

    Exploratory outcome, investigator-developed

    Time frame: 3- and 6-months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).

Access criteria: Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2029, 28 months later.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 28 months is close to that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846735
Responsible party
Kym Ahrens (Principal Investigator, Seattle Children's Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Sep 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion